|
Gene: RNF14 |
Gene summary for RNF14 |
Gene summary. |
Gene information | Species | Human | Gene symbol | RNF14 | Gene ID | 9604 |
Gene name | ring finger protein 14 | |
Gene Alias | ARA54 | |
Cytomap | 5q31.3 | |
Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q9UBS8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9604 | RNF14 | LZE4T | Human | Esophagus | ESCC | 2.15e-10 | 2.32e-01 | 0.0811 |
9604 | RNF14 | LZE5T | Human | Esophagus | ESCC | 1.48e-03 | 2.23e-01 | 0.0514 |
9604 | RNF14 | LZE7T | Human | Esophagus | ESCC | 2.75e-03 | 2.09e-01 | 0.0667 |
9604 | RNF14 | LZE24T | Human | Esophagus | ESCC | 2.70e-11 | 3.16e-01 | 0.0596 |
9604 | RNF14 | LZE6T | Human | Esophagus | ESCC | 1.86e-03 | 1.94e-01 | 0.0845 |
9604 | RNF14 | P2T-E | Human | Esophagus | ESCC | 6.67e-17 | 2.39e-01 | 0.1177 |
9604 | RNF14 | P4T-E | Human | Esophagus | ESCC | 4.69e-04 | 2.34e-01 | 0.1323 |
9604 | RNF14 | P5T-E | Human | Esophagus | ESCC | 1.82e-10 | 2.01e-01 | 0.1327 |
9604 | RNF14 | P8T-E | Human | Esophagus | ESCC | 5.42e-11 | 1.39e-01 | 0.0889 |
9604 | RNF14 | P9T-E | Human | Esophagus | ESCC | 3.74e-10 | 1.45e-01 | 0.1131 |
9604 | RNF14 | P10T-E | Human | Esophagus | ESCC | 1.65e-22 | 2.12e-01 | 0.116 |
9604 | RNF14 | P11T-E | Human | Esophagus | ESCC | 1.09e-16 | 5.51e-01 | 0.1426 |
9604 | RNF14 | P12T-E | Human | Esophagus | ESCC | 1.17e-23 | 4.84e-01 | 0.1122 |
9604 | RNF14 | P15T-E | Human | Esophagus | ESCC | 2.41e-12 | 2.69e-01 | 0.1149 |
9604 | RNF14 | P16T-E | Human | Esophagus | ESCC | 3.33e-14 | 2.76e-01 | 0.1153 |
9604 | RNF14 | P17T-E | Human | Esophagus | ESCC | 2.80e-05 | 2.27e-01 | 0.1278 |
9604 | RNF14 | P19T-E | Human | Esophagus | ESCC | 4.41e-06 | 5.15e-01 | 0.1662 |
9604 | RNF14 | P20T-E | Human | Esophagus | ESCC | 5.40e-15 | 4.36e-01 | 0.1124 |
9604 | RNF14 | P21T-E | Human | Esophagus | ESCC | 2.64e-11 | 2.75e-01 | 0.1617 |
9604 | RNF14 | P22T-E | Human | Esophagus | ESCC | 7.57e-25 | 4.50e-01 | 0.1236 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | |
Skin | AK | |
Skin | SCCIS | |
Skin | cSCC | |
Thyroid | HT |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004217610 | Cervix | CC | regulation of protein catabolic process | 104/2311 | 391/18723 | 9.39e-15 | 9.36e-12 | 104 |
GO:004586210 | Cervix | CC | positive regulation of proteolysis | 95/2311 | 372/18723 | 1.84e-12 | 6.86e-10 | 95 |
GO:190336210 | Cervix | CC | regulation of cellular protein catabolic process | 72/2311 | 255/18723 | 5.98e-12 | 2.10e-09 | 72 |
GO:004573210 | Cervix | CC | positive regulation of protein catabolic process | 65/2311 | 231/18723 | 7.44e-11 | 1.39e-08 | 65 |
GO:001049810 | Cervix | CC | proteasomal protein catabolic process | 111/2311 | 490/18723 | 8.98e-11 | 1.58e-08 | 111 |
GO:000989610 | Cervix | CC | positive regulation of catabolic process | 109/2311 | 492/18723 | 5.26e-10 | 6.99e-08 | 109 |
GO:190305010 | Cervix | CC | regulation of proteolysis involved in cellular protein catabolic process | 60/2311 | 221/18723 | 1.82e-09 | 1.98e-07 | 60 |
GO:200005810 | Cervix | CC | regulation of ubiquitin-dependent protein catabolic process | 47/2311 | 164/18723 | 1.63e-08 | 1.25e-06 | 47 |
GO:004316110 | Cervix | CC | proteasome-mediated ubiquitin-dependent protein catabolic process | 91/2311 | 412/18723 | 1.65e-08 | 1.25e-06 | 91 |
GO:003133110 | Cervix | CC | positive regulation of cellular catabolic process | 91/2311 | 427/18723 | 9.64e-08 | 5.25e-06 | 91 |
GO:00002097 | Cervix | CC | protein polyubiquitination | 58/2311 | 236/18723 | 1.57e-07 | 7.41e-06 | 58 |
GO:190336410 | Cervix | CC | positive regulation of cellular protein catabolic process | 43/2311 | 155/18723 | 1.80e-07 | 8.28e-06 | 43 |
GO:006113610 | Cervix | CC | regulation of proteasomal protein catabolic process | 48/2311 | 187/18723 | 4.63e-07 | 1.77e-05 | 48 |
GO:003243410 | Cervix | CC | regulation of proteasomal ubiquitin-dependent protein catabolic process | 38/2311 | 134/18723 | 4.99e-07 | 1.88e-05 | 38 |
GO:19030528 | Cervix | CC | positive regulation of proteolysis involved in cellular protein catabolic process | 34/2311 | 133/18723 | 2.28e-05 | 4.01e-04 | 34 |
GO:200006010 | Cervix | CC | positive regulation of ubiquitin-dependent protein catabolic process | 29/2311 | 107/18723 | 2.77e-05 | 4.62e-04 | 29 |
GO:00324369 | Cervix | CC | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 25/2311 | 90/18723 | 6.22e-05 | 8.90e-04 | 25 |
GO:19018008 | Cervix | CC | positive regulation of proteasomal protein catabolic process | 29/2311 | 114/18723 | 9.71e-05 | 1.27e-03 | 29 |
GO:004586225 | Cervix | N_HPV | positive regulation of proteolysis | 29/534 | 372/18723 | 1.08e-06 | 5.80e-05 | 29 |
GO:190336225 | Cervix | N_HPV | regulation of cellular protein catabolic process | 22/534 | 255/18723 | 4.31e-06 | 1.66e-04 | 22 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RNF14 | SNV | Missense_Mutation | c.232N>C | p.Glu78Gln | p.E78Q | Q9UBS8 | protein_coding | tolerated(0.13) | benign(0.241) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
RNF14 | SNV | Missense_Mutation | c.1234G>C | p.Glu412Gln | p.E412Q | Q9UBS8 | protein_coding | tolerated(1) | benign(0.122) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RNF14 | insertion | Frame_Shift_Ins | novel | c.445_446insTA | p.Gly149ValfsTer20 | p.G149Vfs*20 | Q9UBS8 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
RNF14 | insertion | Nonsense_Mutation | novel | c.446_447insACAGAGGGAAGTGGTTTTAGTTTTCTAAAACCTTATTCCTTA | p.Gly149_Ser150insGlnArgGluValValLeuValPheTerAsnLeuIleProTyr | p.G149_S150insQREVVLVF*NLIPY | Q9UBS8 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
RNF14 | insertion | In_Frame_Ins | novel | c.860_861insAGG | p.Leu287_Phe288insGly | p.L287_F288insG | Q9UBS8 | protein_coding | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
RNF14 | insertion | In_Frame_Ins | novel | c.149_150insTACAGGCAC | p.Val50_Ser51insThrGlyThr | p.V50_S51insTGT | Q9UBS8 | protein_coding | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
RNF14 | insertion | In_Frame_Ins | novel | c.153_154insCACCGC | p.Ser51_Gly52insHisArg | p.S51_G52insHR | Q9UBS8 | protein_coding | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
RNF14 | SNV | Missense_Mutation | rs138952656 | c.1340A>G | p.Asn447Ser | p.N447S | Q9UBS8 | protein_coding | tolerated(0.25) | benign(0.003) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
RNF14 | SNV | Missense_Mutation | c.841N>C | p.Glu281Gln | p.E281Q | Q9UBS8 | protein_coding | tolerated(0.45) | benign(0.046) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
RNF14 | SNV | Missense_Mutation | novel | c.346N>C | p.Glu116Gln | p.E116Q | Q9UBS8 | protein_coding | deleterious(0.04) | possibly_damaging(0.649) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |